Life Insurance Drug Test

Life insurance drug testing catches two things most applicants don't expect: undisclosed tobacco use and prescription drug context. The test results alone don't determine your outcome—how those results align with what you disclosed on your application does. A prescription opioid that's on your medical records and disclosed up front is treated completely differently from one that shows up with no documented history. This page covers exactly what carriers test for, how each substance class is underwritten, and what to disclose—and when—to avoid a denial or policy rescission. For a broader look at how carriers evaluate risk, see the life insurance underwriting process or the full underwriting hub. As an independent agency, Insurance Geek places life insurance cases with substance histories across 30+ A-rated carriers—matching each profile to the carrier whose underwriting guidelines actually fit before a formal application goes in.

Key Takeaways

• Blood and urine screens look back 1–3 days for most substances in blood, up to 30+ days in urine depending on the substance and frequency of use.
• Cotinine (the nicotine metabolite) remains detectable in urine for 3–4 weeks after last use—applying as a non-smoker while testing positive typically voids the policy.
• Marijuana underwriting has shifted significantly since 2021; some carriers now offer Preferred-class rates to occasional recreational users.
• Disclosed prescription use—even opioids or benzodiazepines—is evaluated in context. Undisclosed use triggers misrepresentation concerns regardless of the underlying condition.
• A documented history of substance abuse is not an automatic denial, but timing matters: most carriers require 2–5 years clean depending on the substance.

What Life Insurance Drug Tests Screen For

The standard life insurance blood and urine test is collected during the paramedical exam by a licensed examiner. Labs run a panel that typically covers the following substance classes:

• Nicotine/cotinine — the primary metabolite of nicotine use; present whether the applicant smokes, vapes, or uses nicotine patches
• Marijuana (THC/THC-COOH) — the active compound and its inactive metabolite, which persists in urine far longer
• Cocaine and metabolites — including benzoylecgonine, which remains detectable after the high has cleared
• Opiates and opioids — morphine, codeine, heroin metabolites, and synthetic opioids such as oxycodone and fentanyl
• Amphetamines and methamphetamine — including MDMA
• Benzodiazepines — Valium (diazepam), Xanax (alprazolam), Klonopin, and similar medications
• Barbiturates — less common today but still screened
• Phencyclidine (PCP)
• Anabolic steroids — depending on the carrier and face amount
• Methadone — typically its own screened metabolite (EDDP)

Not every carrier runs every panel on every application. Face amount and age influence what gets tested. Higher face amounts—typically $1M and above—often trigger expanded screening.

Detection Windows: Blood vs. Urine

Detection window is one of the most practical pieces of information for any applicant preparing for the paramedical exam.

Blood tests offer a shorter but more accurate picture of recent use. Most substances clear the bloodstream within 1–3 days. THC is an exception: in heavy daily users, THC can remain in blood for up to 7 days. Cotinine has a blood half-life of around 20 hours, but labs can detect it for 1–3 days depending on use frequency.

Urine tests reach further back and are far more common in paramedical screens. Detection windows vary significantly by substance and frequency of use:

For hair follicle testing—less common but used on large-face-amount applications at some carriers—detection windows extend to approximately 90 days.

How Each Substance Class Is Underwritten

Nicotine and Cotinine

This is the most common drug testing issue underwriters see. Cotinine—the metabolite the body produces as it processes nicotine—shows up in both blood and urine and is highly accurate. It doesn't distinguish between cigarettes, cigars, vaping, chewing tobacco, or nicotine patches.

Applying as a non-smoker while testing positive for cotinine is treated as misrepresentation. Carriers can deny the claim and rescind the policy even after it's issued. If you use any form of nicotine, apply as a tobacco user—the premium difference between smoker and non-smoker rates is significant, but a rescinded policy pays nothing.

Most carriers will reclassify you as a non-smoker if you've been tobacco-free for 12 consecutive months, though some require 3–5 years depending on the product and health class.

Marijuana — Recreational and Medical Use

Marijuana underwriting has changed more in the past three years than any other category on this page. The blanket "smoker rates if you test positive" stance that most carriers held before 2022 is no longer universal.

Where the market stands now:

• Several major carriers—including Lincoln Financial, Prudential, and Transamerica—have issued updated guidelines offering non-smoker rates to recreational marijuana users, typically defined as occasional use (once a week or less, sometimes up to 2–3 times per week depending on the carrier).
• Medical marijuana users with documented physician oversight are generally viewed more favorably than undisclosed recreational use, because the paper trail shows the use is being managed.
• Heavy daily use continues to raise concerns—not primarily because of THC itself, but because underwriters assess the underlying reason for heavy use (anxiety, chronic pain, sleep disorders) as part of the health picture.
• Some carriers still apply tobacco/smoker rates to any positive THC result regardless of frequency. Carrier selection matters here.

The practical implication: if you use marijuana, work with someone who knows current carrier guidelines by substance class. Applying blind to a carrier with a strict stance when a lenient one would offer you Preferred rates is the avoidable part.

Life Insurance

Not sure how your marijuana use affects your rate?

Run My Numbers

Prescription Drugs — The Most Important Section on This Page

Prescription drug results are the most misunderstood part of life insurance drug testing, and getting it wrong is more costly than any other underwriting mistake.

Disclosed prescription use is not a red flag on its own. Underwriters expect to see medications in the blood and urine. What they're evaluating is whether the medications are consistent with your disclosed medical history and treatment plan. A disclosed opioid prescription for a documented back condition, filled at a single pharmacy, with regular physician oversight, is a very different picture from opioids showing up with no medical history on record.

Undisclosed prescription use is a serious problem. If a controlled substance shows up in your sample with no matching history on the application, the underwriter now has two concerns: the condition driving the prescription (which wasn't disclosed) and the question of whether the applicant is obtaining controlled substances outside of legitimate medical channels. Either path leads to a declined application or misrepresentation concerns post-issue.

Common prescription classes and how they're viewed:

Opioids (oxycodone, hydrocodone, morphine, fentanyl, tramadol) — Chronic opioid use for ongoing pain management typically results in a table rating (higher premium) or postponement, depending on the underlying condition's severity and whether the dosage has been stable. Recent dose escalation or multiple prescribers is a red flag. Disclosed use with stable dosing and a clear treating physician is often insurable, sometimes at substandard rates.

Benzodiazepines (Xanax, Klonopin, Valium, Ativan) — Disclosed benzo use for anxiety or sleep is evaluated in the context of the underlying condition. Low-dose, long-term prescriptions with a stable history are generally more favorably viewed than recent starts or dose increases. High-dose benzo use raises concerns about dependence, which is evaluated separately from the anxiety or sleep disorder it's treating.

ADHD medications (Adderall, Vyvanse, Ritalin, Concerta) — Disclosed ADHD medication is typically not a significant rating factor on its own. Underwriters look at the underlying ADHD diagnosis, whether the condition is controlled, and whether there are any associated behavioral or psychiatric comorbidities.

Antidepressants and antipsychotics — A disclosed SSRI for mild to moderate depression is generally not a rating factor for most carriers. The severity, duration, hospitalization history, and any associated conditions (bipolar, psychotic episodes, suicidality in the past) drive the underwriting decision—not the medication class itself.

Methadone and buprenorphine (Suboxone) — These are opioid use disorder (OUD) treatment medications. Most traditional fully underwritten carriers will postpone for 1–3 years from the start of stable treatment before reconsidering. Simplified issue products are often available sooner.

Cocaine

Cocaine with no documented history is typically a decline in the current application cycle. Most carriers will consider an applicant who discloses prior use if there's a clean medical record and substantial abstinence—usually 3–5 years. Current use or a positive screen at the time of the exam is a decline at virtually every carrier writing fully underwritten life insurance.

Amphetamines and Methamphetamine

Methamphetamine is a decline, full stop, at every traditional carrier during active use and for multiple years following. Carriers typically require 5–10 years of verified abstinence before reconsidering, and even then it's a high-scrutiny application. Non-prescribed amphetamine use is treated similarly.

Anabolic Steroids

Non-prescribed anabolic steroid use triggers a table rating to decline depending on frequency, history, and associated health markers (elevated LFTs, abnormal lipid panels, heart size). Steroids are an underwriting concern primarily because of secondary cardiovascular effects, not because of the substance class itself. Disclosed therapeutic testosterone replacement prescribed by a physician is evaluated differently—usually as a health rating based on the underlying condition driving the prescription.

History of Past Drug Abuse — What Underwriters Actually Look At

A history of substance abuse or addiction is not an automatic permanent decline. It falls into the broader category of high-risk life insurance—underwriters evaluate it as a risk with a timeline, and the further back it is, the less weight it carries.

What underwriters want to see:

• A documented treatment episode (rehab, outpatient program, MAT) shows the problem was acknowledged and addressed—this is better than untreated use that "just stopped."
• Sustained abstinence. Most carriers require 2 years clean for alcohol, 3–5 years for opioids or stimulants, and 5–10 years for methamphetamine.
• Stable employment and living situation signal recovery that's holding.
• No secondary consequences still active—DUI within 3 years, probation, active liver disease from alcohol use.
• No multiple relapses or multiple treatment episodes in the recent past.

What the application will ask: date of last use, substance(s) involved, treatment history (dates, type, completion), any legal history tied to use, current support structure, and the attending physician's name for records.

For applicants within the required abstinence window, guaranteed issue life insurance is often available without a drug screen—coverage amounts are typically limited to $25,000–$50,000, but it provides something while a fully underwritten option isn't accessible.

Most applicants with 3+ years of clean history and no secondary health complications can qualify for a fully underwritten policy, often at substandard (table-rated) rates. The table rating improves as the timeline extends. By 5–7 years, some carriers will offer Standard rates.

FAQ

Life Insurance

Applying with a substance history? Get matched to the right carrier first.

Run My Numbers